Emergent BioSolutions: U.S. Government Issues Request for Proposal for the Supply of 44.75 Million Doses of BioThrax over Next 5 Years

Emergent BioSolutions Inc. (NYSE:EBS) today announced that the U.S. government has indicated its intention to award Emergent a sole source contract (RFP-2011-N-13414) for the purchase of 44.75 million doses of BioThrax® (Anthrax Vaccine Adsorbed) for inclusion in the Strategic National Stockpile (SNS) over a 5 year period. BioThrax is the only vaccine licensed by the U.S. Food and Drug Administration (FDA) to protect against anthrax infection. Emergent anticipates finalizing a contract with the U.S. government during the third quarter of 2011.